Clinical management of BRCA1 and BRCA2 mutation carriers
- 25 September 2006
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 25 (43), 5825-5831
- https://doi.org/10.1038/sj.onc.1209881
Abstract
The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.Keywords
This publication has 66 references indexed in Scilit:
- Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)JNCI Journal of the National Cancer Institute, 2006
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2004
- BRCA germline mutations in Jewish women with uterine serous papillary carcinomaGynecologic Oncology, 2004
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- A Genetic Epidemiological Study of Carcinoma of the Fallopian TubeGynecologic Oncology, 2001